---
title: Psilocybin Psilocin
description: 
published: true
date: 2025-08-08T02:12:20.643Z
tags: chemicals
editor: markdown
dateCreated: 2025-08-08T02:12:18.399Z
---

| **Other Names** | **Literature** |
|---|---|
| Psilocybin: CY-39, indocybin, 0-phosphoryl-4hydroxy-<br>N,N-dimethyltryptamine, 3(2-dimethylamino)<br>ethylindol-4-01 dihydrogenphosphatester<br><br>Psilocin: 4-hydroxy-N,N-dimethyltryptamine,<br>psilocine, psilocyn (misspelling in the legal literature),<br>3- [2-(dimethylamino)ethyl]-1H-indole-4-01<br><br>Empirical formula: C12H17N204P (psilocybin),<br>C12H16N20 (psilocin)<br><br>Substance type: tryptamines, indole amines (indole<br>alkaloids)<br><br>Psilocybin was first isolated from [Psilocybe mexicana](/en/psilocybe-mexicana)<br>and identified by Albert Hofmann in 1955<br>(Hofmann et al. 1958, 1959). The phosphorylated<br>indole amine psilocybin is transformed into<br>psilocin by splitting off the phosphoric acid group<br>(Hofmann and Troxler 1959). Because the<br>protection the phosphoric acid would provide is<br>lacking, psilocin easily oxidizes with the phenolic hydroxyl group, resulting in blue quinonoid products.<br>This explains why psilocybin mushrooms<br>turn blue after they have been squeezed and<br>harvested (cf. [Panaeolus cyanescens](/en/panaeolus-cyanescens), [Psilocybe cyanescens](/en/psilocybe-cyanescens)).<br>In the body, psilocybin is immediately<br>metabolized into psilocin, which is the actual<br>psychoactive constituent.<br><br>Psilocybin and psilocin are closely related to<br>baeocystin (= 0-phosphoryl-4-hydroxy-N-methyltryptamine,<br>norpsilocybin), which probably represents<br>the biogenic precursor of psilocybin (Repke<br>et al. 1977; cf. also Brack et al. 1961 and Chilton et<br>al. 1979). Baeocystin may be a derivative of tryptophan<br>(Brack et al. 1961).<br><br>The usual psychedelic dosage of psilocybin is<br>10 mg. When psilocybin is taken orally, the effects<br>typically become apparent in about twenty<br>minutes (Shulgin 1980). Rudolf Gelpke (1928-1972)<br>took between 6 and 20 mg during his self-experiments;<br>with 10 mg, he made his historic<br>"journey to the outer space of the soul": This inebriation was a space flight not into the<br>outer realm, but into the inner person, and for<br>a moment I experienced reality from a<br>position located somewhere beyond the<br>gravity of time. (Gelpke 1962,395)<br><br>With very high dosages, it is common to perceive<br>voices (Beach 1997). This could explain why<br>Indians say that the mushroom talks to them.<br>Toxic dosages are unknown!<br><br>Walter Pahnke's "Good Friday experiment," in<br>which theology students were administered psilocybin<br>in a church on Good Friday, has become<br>renowned. Pahnke applied the theory of dosage,<br>set, and setting as part of the test to see whether<br>mystical revelations would occur, which was<br>indeed the case (Pahnke 1972; Pahnke and<br>Richards 1970; cf. Doblin 1991).<br><br>Timothy Leary and his colleagues at Harvard<br>experimented with psilocybin on prisoners. Their<br>experiments were aimed at determining whether<br>the psychedelic constituent was suitable for use in<br>therapy with inmates. It was hoped that the drug<br>experience would enable the prisoners to attain<br>insights into their behavior that would then enable<br>them to change themselves on their own. Although<br>these experiments showed great promise, they had<br>to be terminated (Clark 1970; Forcier and Doblin<br>1994; Riedlinger and Leary 1994).<br><br>Both psilocybin and two synthetic derivatives<br>(CZ-74, CY-19) have been used with success in<br>psychedelic and psycholytic therapy (Leuner 1963;<br>Leuner and Baer 1965; Passie 1995, 1996). Psilocybin<br>can release, stimulate, and inspire creativity<br>(Fischer et al. 1972), as an increasing number of<br>studies have shown (Baggott 1997; Spitzer et al.<br>1996), and "archetypal art therapy" is making use<br>of this effect (Allen 1995).<br><br>Today, psilocybin is playing a central role in<br>neurochemical research into brain activity, in<br>which it is being studied with the very elaborate<br>and costly positron-emission tomography (PET)<br>method (Vollenweider 1996).<br><br>Jochen Gartz has discovered that fungal<br>enzymes synthesize the "synthetic" psilocin analog<br>CZ-74 (diethyl-4-hydroxytryptamine, 4-0H-DET)<br>from diethyltryptamine when it is added to a<br>[Psilocybe spp.](/en/psilocybe-spp) substrate (J. Gartz, pers. comm.). It<br>is possible that the "synthetic" CY-19 (= diethyl-4-phosphoryloxytryptramine)<br>can be produced in<br>the same fashion.<br><br>**Commercial Forms and Regulations**<br><br>Both psilocybin and psilocin are classified as<br>Schedule I drugs in the United States (Shulgin<br>1980). They are internationally regarded as illegal<br>"narcotics." The analog substances psilocin-(eth)<br>and psilocybin-(eth) are also illegal (Korner 1994,<br>40*). | See also the entries for [Psilocybe mexicana](/en/psilocybe-mexicana) and<br>[Psilocybe spp.](/en/psilocybe-spp)<br><br>Allen, Tamara D. 1994. Research in archetypal art<br>therapy with psilocybin. Maps 5 (1): 39-40.<br><br>---. 1995. Archetypal art therapy: Hearing<br>psilocybin in the art & metaphor work of<br>volunteer no. 31. Maps 6 (1): 23-26.<br><br>Baggot, Matthew. 1997. Psilocybin's effects on<br>cognition: Recent research and its implications<br>for enhancing creativity. Maps 7 (1): 10-11.<br><br>Beach, Horace. 1997. Listening for the logos: Study<br>of reports of audible voices at high doses of<br>psilocybin. Maps 7 (1): 12-17.<br><br>Bocks, S. M. 1968. The metabolism of psilocin and<br>psilocybin by fungal enzymes. Biochemical<br>Journal 106:12-13.<br><br>Borner, Stefan, and Rudolf Brenneisen. 1987.<br>Determination of tryptamines in hallucinogenic<br>mushrooms using high-performance liquid<br>chromatography with photodiode array<br>detection. Journal of Chromatography 408:402-8.<br><br>Brack, A., Albert Hofmann. F. Kalberer, H. Kobel,<br>and J. Rutschmann. 1961. Tryptophan als<br>biogenetische Vorstufe des Psilocybins. Archiv der<br>Pharmazie 294/66 (4): 230-34.<br><br>Chilton, W. Scott, Jeremy Bigwood, and Robert E.<br>Jensen. 1979. Psilocin, bufotenine, and serotonin:<br>Historical and biosynthetic observations. Journal<br>of Psychedelic Drugs 11 (1-2): 61-69.<br><br>Clark, Jonathan. 1970. Psilocybin: The use of<br>psilocybin in a prison. In Psychedelics, ed.<br>Bernard Aaronson and Humphry Osmond,<br>40-44. Garden City, N.Y.: Anchor Books.<br><br>Doblin, Rick. 1991. Pahnke's (Good Friday<br>experiment': A long-term follow-up and<br>methodological critique. The Journal of<br>Transpersonal Psychology 23 (1): 1-28.<br><br>Fischer, Roland, Ronald Fox, and Mary Ralstin. 1972.<br>Creative performance and the hallucinogenic<br>drug-induced creative experience. Journal of<br>Psychedelic Drugs 5 (1): 29-36. (On psilocybin<br>and creativity research.)<br><br>Forcier, Michael W., and Rick Doblin. 1994. Long-term<br>follow-up to Leary's Concord Prison<br>psilocybin study. Maps 4 (4): 20-21.<br><br>Gelpke, Rudolf. 1962. Von Fahrten in den Weltraum<br>der Seele: Berichte tiber Selbstversuche mit<br>Delysid (LSD) und Psilocybin (CY). Antaios<br>3:393-411.<br><br>---. [1997]. Von Fahrten in den Weltraum der<br>Seele: Berichte uber Selbstversuche mit LSD und<br>Psilocybin. Lohrbach: Werner Pieper's<br>MedienXperimente and Edition Rauschkunde.<br><br>Gnirss, Fritz. 1959. Untersuchung mit Psilocybin,<br>einem Phantastikum aus dem mexikanischen<br>Rauschpilz Psilocybe mexicana. Schweizer Archiv<br>fur Neurologie, Neurochirurgie und Psychiatrie<br>84:346-48.<br><br>Hofmann, Albert, A. Frey, H. Ott, Th. Petrzilka, and<br>F. Troxler. 1958. Konstitutionsautklarung und<br>Synthese von Psilocybin. Experientia 14 (11):<br>397-401.<br><br>Hofmann, Albert, Roger Heim, A. Brack, and H.<br>Kobel. 1958. Psilocybin, ein psychotroper<br>Wirkstoff aus dem mexikanischen Rauschpilz<br>Psilocybe mexicana Heim. Experientia 14 (3):<br>107-12.<br><br>Hofmann, Albert, Roger Heim, A. Brack, H. Kobel,<br>A. Frey, H. Ott, T. Petrzilka, and F. Troxler. 1959.<br>Psilocybin und Psilocin, zwei psychotrope<br>Wirkstoffe aus mexikanischen Rauschpilzen.<br>Helvetica Chimica Acta 42 (162): 1557-72.<br><br>Hofmann, Albert, and F. Troxler. 1959.<br>Identifizierung von Psilocin. Experientia 15 (3):<br>101-4.<br><br>Jones, Richard. 1963. "Up" on Psilocybin. The<br>Harvard Review 1 (4): 38-43.<br><br>Krippner, Stanley. 1970. Psilocybin: An adventure in<br>psilocybin. In Psychedelics, ed. Bernard Aaronson<br>and Humphry Osmond, 35-39, Garden City,<br>N.Y.: Anchor Books.<br><br>Laatsch, Hartmut. 1994. Das Fleisch der Götter-Von<br>den Rauschpilzen zur Neurotransmission. In<br>Welten des Bewußtseins, ed. A. Dittrich et al.,<br>3:181-95. Berlin: VWB.<br><br>---. 1996. Zur Pharmakologie von Psilocybin<br>und Psilocin. In Maria Sabina-Botin der heiligen<br>Pilze, ed. Roger Liggenstorfer and Christian<br>Rätsch, 193-202. Solothurn: Nachtschatten<br>Verlag.<br><br>Leuner, Hanscarl. 1963. Die Psycholytische Therapie:<br>Klinische Psychotherapie mit Hilfe von LSD-25<br>und verwandten Substanzen. Zeitschrift fur<br>Psychotherapie und medizinische Psychologie<br>13:57 ff.<br><br>Leuner, Hanscarl, and G. Baer. 1965. Two short-acting<br>hallucinogens of the psilocybin-group. In<br>Neuro-pharmacology, ed. D. Bente and P. B.<br>Bradley. Amsterdam: Elsevier.<br><br>Ott, Jonathan, and Gaston Guzman. 1976. Detection<br>of psilocybin in species of Psilocybe, Panaeolus<br>and Psathyrella. Lloydia 39:258-60.<br><br>Pahnke, Walter N. 1972. Drogen und Mystik. In<br>Josuttis and Leuner, 54-76*.<br><br>Pahnke, Walter N., and William A. Richards. 1970.<br>Implications of LSD and experimental<br>mysticism. Journal of Psychedelic Drugs 3 (1):<br>92-108.<br><br>Passie, Torsten. 1995. Psilocybin in der westlichen<br>Psychotherapie. Curare 18 (1): 131-52.<br><br>---. 1996. Psilocybin in der westlichen<br>Psychotherapie. In Maria Sabina-Botin der<br>heiligen Pilze, ed. Roger Liggenstorfer and<br>Christian Rätsch, 211-25. Solothurn:<br>Nachtschatten Verlag.<br><br>Repke, David B., Dale Thomas Leslie, and Gaston<br>Guzman. 1977. Baeocystin in Psilocybe, Conocybe<br>and Panaeolus. Lloydia 40 (6): 566-78.<br><br>Riedlinger, Thomas, and Timothy Leary. 1994.<br>Strong medicine for prisoner reform: The<br>Concord Prison experiments. Maps 4 (4): 22-25.<br><br>Shulgin, Alexander T. 1980. Psilocybin. Journal of<br>Psychedelic Drugs 12 (1): 79.<br><br>Spitzer, M., M. Thimm, L. Hermle, P. Holzmann, K.<br>A. Kovar, H. Heimann, E. Gouzoulis-Mayfrank,<br>U. Kischka, and F. Schneider. 1996. Increased<br>activation of indirect semantic associations<br>under psilocybin. Biological Psychiatry<br>39:1055-57.<br><br>Strassmann, Rick. 1992. DMT and psilocybin<br>research. Maps 3 (4): 8-9.<br><br>---. 1995. University of New Mexico DMT and<br>psilocybin studies. Maps 5 (3): 14-15.<br><br>Troxler, F., F. Seemann, and Albert Hofmann. 1959.<br>Abwandlungsprodukte von Psilocybin und<br>Psilocin. Helvetica Chimica Acta 42 (226):<br>2073-103.<br><br>Vollenweider, Franz. 1996. Perspektiven der<br>Bewußtseinsforschung mit Halluzinogenen. In<br>Maria Sabina-Botin der heiligen Pilze, ed. Roger<br>Liggenstorfer and Christian Rätsch, 203-10.<br>Solothurn: Nachtschatten Verlag. |